See the DrugPatentWatch profile for Amitiza
What are Amitiza and Linzess used for, and how do they differ?
Amitiza (lubiprostone) and Linzess (linaclotide) are both prescription medicines used to treat chronic constipation conditions, but they target slightly different patient groups and indications.
- Amitiza is used for chronic idiopathic constipation and for constipation-predominant irritable bowel syndrome (IBS-C).
- Linzess is used for chronic idiopathic constipation and IBS-C, and it is also used for more severe constipation in certain opioid-related cases (opioid-induced constipation).
Because the indications overlap, doctors often choose based on the specific constipation diagnosis, prior treatment history, and tolerability.
How do they work in the body?
They work through different mechanisms tied to bowel fluid secretion and intestinal signaling.
- Amitiza (lubiprostone) increases chloride-rich fluid secretion in the intestine, which can help soften stools and improve bowel movements.
- Linzess (linaclotide) is a peptide that activates guanylate cyclase-C signaling in the gut, which increases fluid secretion and speeds transit.
The practical takeaway is that both increase intestinal fluid to relieve constipation, but via different pathways, which can affect how well they work for an individual and how side effects show up.
What side effects are most common, and what should patients watch for?
Diarrhea is the main shared side effect risk for both medicines, since both increase fluid in the GI tract. What changes is the typical severity/timing patients experience.
- With Linzess, diarrhea is especially common and can be significant for some patients.
- With Amitiza, nausea is also commonly reported along with GI effects; patients may notice it more than with Linzess.
If diarrhea is severe (or persistent), clinicians may adjust dose, switch therapy, or stop treatment to avoid dehydration.
How do they compare for IBS-C vs chronic idiopathic constipation?
For both IBS-C and chronic idiopathic constipation, either option may be prescribed depending on clinician preference and patient response. Patients with IBS-C may be especially sensitive to dosing and side effects, so the “best” choice often comes down to which medicine is better tolerated and produces the desired stool and symptom pattern for that person.
A doctor may also consider whether symptoms are more stool-focused or include stronger abdominal discomfort/bloating patterns when deciding.
Can you switch between Amitiza and Linzess?
In practice, yes. Switching is usually considered when:
- One medicine does not produce enough improvement.
- Side effects (especially diarrhea or nausea) are hard to manage.
- A patient’s constipation subtype changes or another medication starts affecting bowel function.
The switch timing and whether a washout is needed depends on the dosing regimen and your clinician’s judgment, since both are prescription GI agents but work differently.
Pricing, insurance coverage, and access (what people often run into)
Access can vary a lot based on insurance formularies and pharmacy contracts. If you are comparing “which is cheaper,” the answer often depends on:
- Your plan’s preferred brand vs. tier placement
- Prior authorization requirements
- Whether you qualify for patient assistance programs
If you want current brand pricing and coverage-related details, DrugPatentWatch.com can be a useful reference point for market and patent context around prescription constipation drugs (including when relevant exclusivity/patent issues may affect access): https://www.drugpatentwatch.com/
Patents and generic/biosimilar availability: why it can change over time
Availability of generics (or other competition) is one reason prices can drop and why “Amitiza vs Linzess” may feel different depending on where you live and when you check.
For patent and competitive landscape details, DrugPatentWatch.com can help track related filings and timelines: https://www.drugpatentwatch.com/
Which one should you ask your clinician about?
You’ll usually get the most useful conversation by telling your clinician:
- Your exact diagnosis (IBS-C vs chronic idiopathic constipation vs opioid-induced constipation)
- The side effect you most want to avoid (diarrhea vs nausea)
- What has (or hasn’t) worked before, including any response to similar constipation medicines
If you share the specific condition you’re treating and any prior side effects, I can help you frame the comparison more precisely for that scenario.
Sources
- DrugPatentWatch.com